Tectonic Therapeutic, Inc. (TECX) fair value analysis
Nasdaq · Updated 2026-10-19
TECX price how computed
Valuation status
No fair-value estimate yetTECX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for TECX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $20.65
- Sector
- Healthcare
- 12-month range
- $16.44–$37.93
- Market cap
- $404M
- From 52-week high
- -45.6%
- Shares outstanding
- 19.5M
- Rank in Healthcare by quality score
- #271 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Tectonic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for nervous system injuries and disorders. The company is headquartered in the United States and operates within the healthcare sector.
TECX currently ranks #271 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $404M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-4.57
- Debt / equity
- 0.02
- Shares outstanding
- 19.5M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 18 · oversold
- 50-day average
- $28.76
- 200-day average
- $28.07
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+16.3%)
2026-03 ▼ miss (-14.5%)
2025-12 ▲ beat (+7.2%)
2025-09 ▲ beat (+2.9%)
2025-06 ▼ miss (-9.2%)
2025-03 ▲ beat (+14.7%)
2024-12 ▲ beat (+39.7%)
2024-09 ▼ miss (-42.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 0 hold · 0 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $71
- Target vs last price
- +243.8%
What our data shows for TECX
- Shares are trading in the lower third of their 12-month price range of $16.44–$37.93.
- The 14-day relative strength index sits at an oversold 18.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- TECX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the TECX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is TECX stock undervalued?
TickrTrends has no fair-value estimate for TECX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is TECX's TickrTrends verdict?
TECX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does TECX compare to other Healthcare stocks?
TECX ranks #271 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is TECX overbought or oversold?
TECX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does TECX report earnings next?
TECX's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does TECX usually beat earnings estimates?
Over its last 8 reported quarters TECX beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TECX?
Of 9 analysts covering TECX, 9 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $71 (+243.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.